CTBO (Cantabio Pharmaceuticals) EBITDA Margin %: 0.00% (As of Dec. 2018)


What is Cantabio Pharmaceuticals EBITDA Margin %?

Cantabio Pharmaceuticals CTBO EBITDA Margin % is 0.00% as of Dec. 2018.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cantabio Pharmaceuticals's EBITDA for the three months ended in Dec. 2018 was $0.69 Mil. Cantabio Pharmaceuticals's Revenue for the three months ended in Dec. 2018 was $0.00 Mil. Therefore, Cantabio Pharmaceuticals's EBITDA margin for the quarter that ended in Dec. 2018 was 0.00%.

Cantabio Pharmaceuticals  (OTCPK:CTBO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Cantabio Pharmaceuticals EBITDA Margin % Related Terms

Cantabio Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals EBITDA Margin % Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CTBO vs TNTY, ETNI, NTRR: EBITDA Margin % Comparison

For the Biotechnology subindustry, Cantabio Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantabio Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantabio Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cantabio Pharmaceuticals's EBITDA Margin % falls into.


Cantabio Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cantabio Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Mar. 2018 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2018 )/Revenue (A: Mar. 2018 )
=-1.392/0
= %

Cantabio Pharmaceuticals's EBITDA Margin % for the quarter that ended in Dec. 2018 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2018 )/Revenue (Q: Dec. 2018 )
=0.69/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Cantabio Pharmaceuticals (CTBO) has a EBITDA Margin % of 0.00% as of Dec. 2018. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' EBITDA Margin % too high?
Cantabio Pharmaceuticals' current EBITDA Margin % is 0.00%.
How does Cantabio Pharmaceuticals' EBITDA Margin % compare to TNTY and ETNI?
Cantabio Pharmaceuticals' EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current EBITDA Margin % is 0.00% as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.